USPTO serial 85706751
ONCORE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Dec 3, 2013
- Examiner
- KHAN, ASMAT A
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 800 means the registration was renewed after acceptable combined Section 8 and Section 9 filings. The mark remains registered for another 10-year term with active federal protection. Calendar the next Section 8 and 9 deadline in 10 years and maintain monitoring.
Need help with ONCORE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Columbia, MD
ADVARRA RESEARCH TECHNOLOGIES, INC.
MADISON, WI
Other trademarks owned by ADVARRA RESEARCH TECHNOLOGIES, INC.
ADVARRA TECHNOLOGY SOLUTIONS, INC.
MADISON, WI
Other trademarks owned by ADVARRA TECHNOLOGY SOLUTIONS, INC.
Madison, WI
Madison, WI
Madison, WI
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Andrew J. Ferren
Andrew J. Ferren Goulston & Storrs PC400 Atlantic AvenueBoston, MA 02110United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Providing downloadable software for use by pharmaceutical companies and others in the design and administration of scientific and medical research projects and of clinical trials for pharmaceuticals, medical devices and medical procedures; Providing downloadable software for use by pharmaceutical companies and others in data collection, data sharing, information exchange, and collaboration regarding scientific and medical research projects and regarding clinical trials for pharmaceuticals, medical devices and medical procedures | ACTIVE | Aug 17, 2012 |
| 035 | Managing databases for use by pharmaceutical companies and others in the design and administration of scientific and medical research projects, and of clinical trials for pharmaceuticals, medical devices and medical procedures; Managing databases for use by pharmaceutical companies and others in the data collection, data sharing, information exchange, and collaboration regarding scientific and medical research projects, and regarding clinical trials for pharmaceuticals, medical devices and medical procedures | ACTIVE | Aug 17, 2012 |
| 042 | Providing on-line non-downloadable software for use in design and administration of scientific and medical research projects, and of clinical trials for pharmaceuticals, medical devices and medical procedures; [ providing a website featuring non-downloadable software for use in the design and administration of scientific and medical research projects, and of clinical trials for pharmaceuticals, medical devices and medical procedures; ] Hosting, managing, developing, and maintaining [ web sites, ] software, and applications for use by pharmaceutical companies and others in the design and administration of scientific and medical research projects, and of clinical trials for pharmaceuticals, medical devices and medical procedures; Providing on-line non-downloadable software for use in data collection, data sharing, information exchange, and collaboration regarding scientific and medical research projects, and regarding clinical trials for pharmaceuticals, medical devices and medical procedures, providing a website featuring non-downloadable software for use in data collection, data sharing, information exchange, and collaboration regarding scientific and medical research projects, and [ regarding clinical trials for pharmaceuticals, medical devices and medical procedures; Hosting, managing, developing, and maintaining [ web sites, ] software, applications, and databases for use by pharmaceutical companies and others in data collection, data sharing, information exchange, and collaboration regarding scientific and medical research projects, and regarding clinical trials for pharmaceuticals, medical devices and medical procedures; Providing on-line non-downloadable software for use by pharmaceutical companies and others in the tracking and management of patients, specimens, equipment, materials, funding, schedules, and performance milestones and metrics involved in scientific and medical research, and in clinical trials for pharmaceuticals, medical devices and medical procedures, providing a website featuring non-downloadable software for use by pharmaceutical companies and others in the tracking and management of patients, specimens, equipment, materials, funding, schedules, and performance milestones and metrics involved in scientific and medical research, and in clinical trials for pharmaceuticals, medical devices and medical procedures; Hosting, managing, developing, and maintaining [ web sites, ] software, and applications for use by pharmaceutical companies and others in the tracking and management of patients, specimens, equipment, materials, funding, schedules, and performance milestones and metrics involved in scientific and medical research, and in clinical trials for pharmaceuticals, medical devices and medical procedures; Providing on-line non-downloadable software for use by pharmaceutical companies and others in the monitoring and reporting of regulatory, standards, and safety compliance in scientific and medical research, and in clinical trials for pharmaceuticals, medical devices and medical procedures, providing a website featuring non-downloadable software for use by pharmaceutical companies and others in the monitoring and reporting of regulatory, standards, and safety compliance in scientific and medical research, and in clinical trials for pharmaceuticals, medical devices and medical procedures; Hosting, managing, developing, and maintaining [ web sites, ] software, and applications for use by pharmaceutical companies and others in the monitoring and reporting of regulatory, standards, and safety compliance in scientific and medical research, and in clinical trials for pharmaceuticals, medical devices and medical procedures; consulting services regarding all of the foregoing | ACTIVE | Aug 16, 2012 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by ADVARRA, INC.
- Other trademarks owned by ADVARRA RESEARCH TECHNOLOGIES, INC.
- Other trademarks owned by ADVARRA TECHNOLOGY SOLUTIONS, INC.
- Other trademarks owned by Forte Research Systems, Inc.
- Other trademarks owned by Forte Research Systems, Inc.
- Other trademarks owned by Forte Research Systems, Inc.
- Other trademarks in Class 009
- Other trademarks in Class 035
- Other trademarks in Class 042
- Similar marks named ONCORE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 27, 2024 | NA89 | NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED | — |
| May 27, 2024 | RNL1 | REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS) | The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active. |
| May 27, 2024 | 89AG | REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED | The USPTO accepted your combined Section 8 declaration and Section 9 renewal application. The registration is renewed for another 10-year term. The next combined maintenance filing will be due at the following 10-year anniversary. |
| May 27, 2024 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Feb 14, 2024 | E89R | TEAS SECTION 8 & 9 RECEIVED | — |
| Jan 25, 2023 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Dec 3, 2022 | REM2 | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | — |
| Nov 2, 2022 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Sep 24, 2021 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Sep 24, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Sep 24, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 24, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 24, 2021 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Sep 22, 2021 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Sep 15, 2021 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Sep 8, 2021 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Dec 6, 2019 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| Dec 6, 2019 | C15A | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Nov 30, 2019 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Oct 25, 2019 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Sep 18, 2019 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Dec 3, 2018 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Apr 29, 2015 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Dec 3, 2013 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 17, 2013 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 17, 2013 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 28, 2013 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 15, 2013 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Aug 14, 2013 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 14, 2013 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 14, 2013 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 14, 2013 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 14, 2013 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Aug 14, 2013 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Aug 7, 2013 | ALIE | ASSIGNED TO LIE | — |
| Jul 25, 2013 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 15, 2013 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 15, 2013 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 15, 2013 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 15, 2012 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 15, 2012 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 15, 2012 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 12, 2012 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 28, 2012 | MPMK | NOTICE OF PSEUDO MARK MAILED | — |
| Aug 27, 2012 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 21, 2012 | NWAP | NEW APPLICATION ENTERED | — |